ALEMTUZUMAB AS A SUBSTITUTE FOR ATG IN THE FBM (FLUDARABINE, BCNU, MELPHALAN) CONDITIONING REGIMEN: COMPARABLE OUTCOMES IN PATIENTS WITH HIGH HCT-CI AND AGE > 60, BUT INFERIOR OUTCOMES IN AML
EHA Library, Andreas Guenther,
4210592
AN EVALUATION OF THE ACCURACY, ACCESSIBILITY, AND CLINICAL RELIABILITY OF A SPECIALIZED AI TOOL FOR SICKLE CELL PATIENT EDUCATION ON WEB AND SOCIAL MEDIA PLATFORMS
EHA Library, Zacharie Liman-Tinguiri,
4210685